Kairos Pharma, Ltd. · AMEX:KAPA
Kairos Pharma — Investor Presentation (2026)
25 slides from Kairos Pharma's investor presentation, 2026
Slide 1: Investor Presentation
INVESTOR PRESENTATION NYSE American: KAPA kairospharma.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation may contain “forward-looking statements” regarding the current expectations and projections about future events of Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”). “Forward-looking statements” (statements as to matters other than historical facts)
Slide 3: Our Mission
OUR MISSION Kairos Pharma is dedicated to advancing therapies to overcome critical challenges in cancer drug resistance and immune suppression. 3
Slide 4: Kairos Highlights: Innovative Cancer Therapeutics
KAIROS HIGHLIGHTS Problem: Resistance develops for even blockbuster drugs like anti-androgen therapies (prostate cancer), Tagrisso (NSCLC) Solution: CD105 elevated with resistance. Our antibody ENV 105 reverses resistance . INNOVATIVE Big opportunities – resistance in prostate cancer, NSCLC, other t
Slide 5: Portfolio of Innovative Drugs
PORTFOLIO OF INNOVATIVE DRUGS DRUG MODALITY/ LEAD IND enabling PHASE 1 PHASE 2 PHASE 3 LEAD INDICATION CANDIDATE MOA IDENTIFICAITON studies CLINICAL TRIALS CLINICAL TRIALS CLINICAL TRIALS Antibody targeting CD105 to US Market reverse resistance to anti- Prostate androgen drugs cancer $6.5B ENV-105 A
Slide 6: Mechanisms of resistance to cancer therapies
Mechanisms of resistance to cancer therapies Cancer Stem Cell
Slide 7: ENV105 Supporting EGFR-Driven Lung Cancer Patients
ENV105 SUPPORTING EGFR-DRIVEN LUNG CANCER PATIENTS – In Phase I Anti-androgen drugs EGFR drugs (enzalutamide, (osimertinib, abiraterone, apalutamide) erlotinib, gefitinib) OSIMERTINIB RESISTANCE IS DEPENDENT ON CD105 • 45,000 EGFR driven NSCLC diagnosed last year • Tagrisso is the standard of care f
Slide 8: ENV105 in EGFR-Driven Lung Cancer
ENV105 in EGFR-Driven Lung Cancer AstraZeneca’s EGFR inhibitor Tagrisso ($7B in 2024 sales) offers only a partial response in 80% of patients CD105 is elevated with Tagrisso treatment Preclinical models show ENV105 can overcome resistance and shrink tumors ENV105 could not only reverse resistance bu
Slide 9: ENV105 in Lung Cancer: NCT05401110
ENV105 IN LUNG CANCER: NCT05401110 PHASE 1Mutations Primary TRIAL FOR EGFR-DRIVEN Resistance Mutations LUNG CANCER: Osimertinib (Tagrisso) + ENV105 Patients that have become resistant to Tagrisso Patients that are incompletely treated with Tagrisso (persistent ctDNA) uing A c c r PRIMARY ENDPOINT: D
Slide 10: ENV105 restores sensitivity to hormone therapy
ENV105 restores sensitivity to hormone therapy Targets CD105-mediated PROSTATE CANCER castrate resistance ENV105 kills cancer cells resistant to AR Tx (H&E stain in PDX model) More differentiated smaller tumors ENV105 inhibits the creation of the AR splice variant which has resistance to AR Tx AR sp
Slide 11: ENV105 in Prostate Cancer
ENV105 IN PROSTATE CANCER PRESENT RANDOMIZED PHASE 2 TRIAL: NCT03418324 Apalutamide with or without ENV105 2 mos. darolutamide 2 mos. uing A c c r darolutamide 2 mos. PRIMARY ENDPOINT: Progression free survival based on RECIST 1.1 and PCWG 3 criteria SECONDARY ENDPOINT: Companion biomarker validatio
Slide 12: Phase 2 Patient Summary NCT05534646
Phase 2 Patient Summary NCT05534646 Patient Apalutamide and ENV105 for the Treatment of Metastatic Castration-Resistant Prostate Cancer Summary Patient Age at Pre-treatment RECIST/PWCG Previous therapies ID enrollment PSA @ week 16 001 68 7.59 Abiraterone Stable disease 002 76 278.55 Enzalutamide, L
Slide 13: Patient Summary: Radiographic PFS points of reference
Radiographic PFS points of reference CARD Trial ARPI-switch median PFS = 3.7 months Cabaxitaxel median PFS = 8 months N=255 100. 90 s< ez 30 £e 70 = a a8 bi ™, ‘se 50 \ 8 3 40 Cabazitaxel 28 304 Androgen- “a BP oo] signaling te tae targeted * 10 inhibitor oF T T T T T T T 0 3 6 9 12 18 24 30 Months
Slide 14: Progression Free Survival NCT05534646
Progression Free Survival NCT05534646 Still on trial w Unrelated withdrawal Median PFS = 15.85 months* * Patients continue to be evaluated w w Months
Slide 15: Percent (%) change in PSA
Change in PSA NCT05534646 Percent (%) change in PSA Comparing baseline pre- treatment PSA to nadir PSA values 35% mean PSA decrease
Slide 16: Radiation Therapy Resistance
Radiation Therapy Resistance ey 1. Enhanced DNA Damage Repair Ged ENV105 PARP inhibitors (carotuximab) Control Rediaten . ontro erapy 2. Tumor Hypoxia BMP2 HIF activated drugs (C305) BMP6 i 3. Cancer Stem Cells a 7 oe TGFBI Blocking Wnt, Hedgehog, and Notch — -| F C BMP9 . TARII||||ALK5 orpaalllacer
Slide 17: Preclinical collaboration: Xofigo with ENV-105
Efficacy and Safety Study of carotuximab (ENV105) and Radium-223 (Xofigo) combination in a bone metastatic mouse model Preclinical collaboration Combining Xofigo with ENV-105 in animal models of bone metastatic prostate cancer Supporting a Phase 2 Clinical Trial Xofigo/ENV-105 combination in bone me
Slide 18: Overcoming Immune Therapy Resistance: KROS-101
Overcoming Immune Therapy Resistance GITR agonist promote cytotoxic T cell expansion and down regulation of immunosuppressive T cells KROS-101
Slide 19: Clinical Trials: CRO consortium
Clinical Trials Primary Mutations Cedars-Sinai Resistance Mutations Medical Center Mayo Clinic CRO consortium leveraging the the Centralized regulatory Stanford efficiencies of each oversight and institutional institute to achieve 40 day investigator-initiated trials Vanderbilt clinical trial activa
Slide 20: Current Non-dilutive funding
Current Non-dilutive funding Primary Mutations Resistance Mutations $3.2M (NCI) ENV105 prostate cancer companion biomarker validation $2.4M (Donor) ENV105 lung cancer preclinical and phase 1 trial $1.8M (DOD) ENV105 lung cancer companion biomarker identification $2.5M (Donor) KROS201 glioblastoma Ph
Slide 21: Strong Intellectual Property Foundation
STRONG INTELLECTUAL PROPERTY FOUNDATION IP extends to 2040 Key IP generated from Murali, Published patents Exclusive, worldwide rights to IP Bhowmick and Yu labs executed internationally licensed from Cedars Sinai Medical Center Pub # KROS101 KROS201 KROS301 KROS401 ENV105 PCT/US2019/045478 PCT/US20
Slide 22: Leading Team
LEADING TEAM John S. Yu, MD Ramchandran Murali, Ph.D VP, RESEARCH AND DEVELOPMENT CEO & CHAIRMAN Professor, Biomedical Sciences and Research in Immunology at Professor of Neurosurgery, Director Surgical Neuro- Penn/Cedars-Sinai Medical Center. Oncology at Cedars-Sinai Medical Center • BAS from Stanf
Slide 23: Independent Directors
INDEPENDENT DIRECTORS Michael Keyoung, MD, Ph.D MD and Ph.D. in Neuroscience and Neurology from Cornell and Sloan Kettering (MSKCC), UCSF Health, Biomedical Fellow at Rockefeller and MSKCC • Senior ME, Head of N.A. for CBC Group, a healthcare-dedicated PE firm with over US$9 Billion AUM • 20+ year c
Slide 24: Kairos Pharma Summary
Kairos Pharma SUMMARY • Clinical stage company with an antibody that impacts a central mechanism of CANCER DRUG RESISTANCE • Pipeline targets IMMUNE SUPPRESSION • Enrolling in phase 1 and 2 trials with interim efficacy data in 2026 • Strategic collaborations with Bayer and upcoming trial with radiol
Slide 25: Investor Relations
INVESTOR RELATIONS Louie Toma MANAGING DIRECTOR CoreIR louie@coreir.com NYSE American: KAPA kairospharma.com